Zalicus presents synergistic drug data at Targeted Cancer Therapies World Europe 2010 meeting

Zalicus Inc. (NASDAQ: ZLCS) presented data today on its discovery of novel synergistic drug combinations for the treatment of cancer at the Targeted Cancer Therapies World Europe 2010 meeting in Zurich on September 23, 2010. During her talk, Margaret Lee, Ph.D., Vice President of Research at Zalicus discussed the role of chemical biology and genomics data in driving hypothesis generation applicable to patient selection and combination therapeutic development.

“These data, which were generated with our combination high-throughput screening (cHTS™) technology, support the rationale that employing a systematic approach to the discovery of novel targets and pathway interactions specific to cancer biology will lead toward development of more selective and efficacious combination therapeutics for a wide variety of cancers”

"These data, which were generated with our combination high-throughput screening (cHTS™) technology, support the rationale that employing a systematic approach to the discovery of novel targets and pathway interactions specific to cancer biology will lead toward development of more selective and efficacious combination therapeutics for a wide variety of cancers," commented Mark H.N. Corrigan, M.D., President and CEO of Zalicus Inc. "Zalicus is continuing to leverage the power of its proprietary cHTS technology through research collaborations with biopharmaceutical companies such as our ongoing oncology research collaboration with Novartis."